Graph AI raises $13.3M for drug-safety workflows
Graph AI is targeting pharmacovigilance, one of pharma’s most regulated and manual operational workflows.
Healthcare AI adoption is increasingly moving into regulated back-office workflows where automation must coexist with strict auditability and human oversight.
What happened
Graph AI raised a $13.3 million Series A led by Insight Partners, with Bessemer participating. Its platform automates operational work inside pharmacovigilance and patient-safety teams, where pharmaceutical companies still process large volumes of safety information manually.
Why it matters
Drug-safety teams handle complex, high-volume information under tight regulatory requirements. That makes pharmacovigilance a difficult but potentially valuable target for AI automation.
The bigger picture
The next wave of healthcare AI may be less visible to patients and more embedded inside pharmaceutical, clinical and regulatory operations. Those workflows can offer clearer ROI than consumer-facing AI tools.